Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study

  • Kim, Gi Hyun (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Chung, Jung Wha (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Lee, Jong Ho (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Ok, Kyeong Sam (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Jang, Eun Sun (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Kim, Jaihwan (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Shin, Cheol Min (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Park, Young Soo (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Hwang, Jin-Hyeok (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Jeong, Sook-Hyang (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Kim, Nayoung (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Lee, Dong Ho (Department of Medicine, Seoul National University Bundang Hospital) ;
  • Kim, Jin-Wook (Department of Medicine, Seoul National University Bundang Hospital)
  • Received : 2015.09.23
  • Accepted : 2015.12.16
  • Published : 2015.12.25
⟨ Previous Next ⟩

Abstract

Background/Aims: Vitamin E improves the biochemical profiles and liver histology in nonalcoholic steatohepatitis, but the role of vitamin E is not clearly defined in the management of nonalcoholic fatty liver disease (NAFLD) which includes both simple steatosis and steatohepatitis. Co-morbid metabolic syndrome increases the probability of steatohepatitis in NAFLD. In this study, we aimed to determine the short-term effects of vitamin E and off-treatment durability of response in a propensity-score matched cohort of NAFLD patients with metabolic syndrome. Methods: A retrospective cohort was constructed by retrieving 526 consecutive NAFLD patients from the electronic medical record data warehouse of a tertiary referral hospital in South Korea. Among them, 335 patients (63.7%) had metabolic syndrome and were eligible for vitamin E therapy. In order to assess the effect of vitamin E, propensity score matching was used by matching covariates between control patients (n=250) and patients who received vitamin E (n=85). Results: The PS-matched vitamin E group (n=58) and control group (n=58) exhibited similar baseline metabolic profiles. After 6 months of vitamin E therapy, the mean ALT levels decreased significantly compared to PS-matched control (P<0.01). The changes in metabolic profiles (body weight, lipid and glucose levels) did not differ between control and vitamin E groups during the study period. Conclusions: Short-term vitamin E treatment significantly reduces ALT levels in NAFLD patients with metabolic syndrome, but metabolic profiles are not affected by vitamin E.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339-350. https://doi.org/10.1055/s-0028-1091978
  2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-285. https://doi.org/10.1111/j.1365-2036.2011.04724.x
  3. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873. https://doi.org/10.1002/hep.21327
  4. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010;59:969-974. https://doi.org/10.1136/gut.2009.205088
  5. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121. https://doi.org/10.1053/j.gastro.2005.04.014
  6. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103:2263-2271. https://doi.org/10.1111/j.1572-0241.2008.02034.x
  7. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023. https://doi.org/10.1002/hep.25762
  8. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152. https://doi.org/10.1172/JCI200422422
  9. Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH. Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol 2006;40(Suppl 1):S51-S60.
  10. Hickman I, Macdonald G. Is vitamin E beneficial in chronic liver disease? Hepatology 2007;46:288-290. https://doi.org/10.1002/hep.21834
  11. Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012;15:641-648. https://doi.org/10.1097/MCO.0b013e328357f747
  12. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685. https://doi.org/10.1056/NEJMoa0907929
  13. Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013;38:134-143. https://doi.org/10.1111/apt.12352
  14. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-348. https://doi.org/10.3350/cmh.2013.19.4.325
  15. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923. https://doi.org/10.1053/jhep.2003.50161
  16. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100. https://doi.org/10.1053/gast.2001.25540
  17. Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006;101:2247-2253. https://doi.org/10.1111/j.1572-0241.2006.00719.x
  18. D’Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine 1998;17:2265-2281. https://doi.org/10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
  19. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.
  20. Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014;147:152-161. https://doi.org/10.1053/j.gastro.2014.02.033
  21. Yoo S, Lee KH, Lee HJ, Ha K, Lim C, Chin HJ, et al. Seoul National University Bundang Hospital’s Electronic System for Total Care. Healthc Inform Res 2012;18:145-152. https://doi.org/10.4258/hir.2012.18.2.145
  22. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-1609. https://doi.org/10.1053/j.gastro.2012.04.001
  23. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-438. https://doi.org/10.1161/01.CIR.0000111245.75752.C6
  24. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480. https://doi.org/10.1111/j.1464-5491.2006.01858.x
  25. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007;22:775-777. https://doi.org/10.1111/j.1440-1746.2007.05002.x
  26. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854. https://doi.org/10.1002/hep.21496
  27. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726-736. https://doi.org/10.1002/hep.24105
  28. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49:80-86. https://doi.org/10.1002/hep.22575
  29. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-129. https://doi.org/10.1002/hep.23276
  30. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-858. https://doi.org/10.1016/j.cgh.2012.03.011
  31. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-1668. https://doi.org/10.1001/jama.2011.520
  32. Polyzos SA, Kountouras J, Zafeiriadou E, Patsiaoura K, Katsiki E, Deretzi G, et al. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst 2011;12:498-503. https://doi.org/10.1177/1470320311402110
  33. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005;54:333-339. https://doi.org/10.2337/diabetes.54.2.333
  34. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379. https://doi.org/10.1053/jhep.2002.30692
  35. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-372. https://doi.org/10.1053/jhep.2002.30690
  36. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005;7:1040-1052. https://doi.org/10.1089/ars.2005.7.1040
  37. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006;12:555-558. https://doi.org/10.1016/j.molmed.2006.10.001
  38. Park K, Gross M, Lee DH, Holvoet P, Himes JH, Shikany JM, et al. Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. Diabetes Care 2009;32:1302-1307. https://doi.org/10.2337/dc09-0259
  39. Phung N, Pera N, Farrell G, Leclercq I, Hou JY, George J. Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int J Mol Med 2009;24:171-180.

Cited by

  1. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design vol.35, pp.2, 2015, https://doi.org/10.1007/s12325-018-0670-8
  2. An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease vol.23, pp.4, 2018, https://doi.org/10.3390/molecules23040877
  3. Gamma-tocopherol ameliorates hyperglycemia-induced hepatic inflammation associated with NLRP3 inflammasome in alloxan-induced diabetic mice vol.13, pp.5, 2019, https://doi.org/10.4162/nrp.2019.13.5.377
  4. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials vol.95, pp.1129, 2015, https://doi.org/10.1136/postgradmedj-2018-136364
  5. VII. The Evidence of Pharmacologic Treatment for NASH vol.109, pp.1, 2020, https://doi.org/10.2169/naika.109.56
  6. Use of a bioengineered antioxidant in mouse models of metabolic syndrome vol.29, pp.2, 2015, https://doi.org/10.1080/13543784.2020.1716216
  7. Use of a bioengineered antioxidant in mouse models of metabolic syndrome vol.29, pp.2, 2015, https://doi.org/10.1080/13543784.2020.1716216
  8. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease vol.166, pp.None, 2015, https://doi.org/10.1016/j.phrs.2021.105517
  9. Can vitamin E supplementation affect obesity indices? A systematic review and meta-analysis of twenty-four randomized controlled trials vol.40, pp.5, 2015, https://doi.org/10.1016/j.clnu.2021.02.002